TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis

Hongwei Yang, Yanchen Xie, Yuan Zhao, Liang Sun, Xiaoquan Zhu, Shuhui Wang, Yongqiang Zhang, Ping Lei, Yunxiao MengMedicine 2017 · DOI

TL;DR

This study investigates the link between genetic variations in the TNFAIP3 gene and myasthenia gravis (MG), a neuromuscular disorder. Researchers found a specific polymorphism (rs7749323) in the TNFAIP3 gene is significantly associated with an increased risk of developing late-onset myasthenia gravis (LOMG) in a Chinese population. This finding highlights TNFAIP3's potential role in the pathogenesis of LOMG and opens avenues for understanding its mechanisms.

What Problem Does This Paper Address?

Myasthenia gravis (MG) is an autoimmune disease characterized by weakness and fatigue due to antibodies attacking the neuromuscular junction. While the exact triggers for this autoimmune response are not fully understood, genetic predisposition is believed to play a significant role. Previous research has implicated the TNFAIP3 gene, which encodes a protein involved in regulating inflammatory responses, in various autoimmune diseases. However, the specific contribution of TNFAIP3 gene variations to the susceptibility of MG, particularly its different clinical subtypes, remained unclear. This paper aims to fill this gap by examining the association between specific TNFAIP3 gene polymorphisms and MG, with a focus on identifying any links to particular clinical presentations.

Methods

The study employed a case-control design, comparing genetic data from adult MG patients with healthy controls.

  • Participant Recruitment: 215 adult MG patients and 235 age- and gender-matched healthy controls from northern Han Chinese populations were recruited. MG patients were further categorized based on clinical features, age of onset, thymic pathology, and autoantibody status.
  • Genotyping: Two specific single nucleotide polymorphisms (SNPs) in the TNFAIP3 gene, rs5029939 and rs7749323, were selected for analysis based on prior genome-wide association studies (GWAS) linking them to immune-mediated diseases. DNA was extracted from peripheral white blood cells. Genotyping was performed using allele-specific PCR for rs7749323 and PCR-based restriction fragment length polymorphism analysis for rs5029939.
  • Statistical Analysis: Standard statistical methods were used to compare allele and genotype frequencies between MG subgroups and healthy controls. This included chi-squared tests, Fisher exact tests, and logistic regression analysis to calculate odds ratios (OR) and confidence intervals (CI), adjusting for age and gender. Hardy-Weinberg equilibrium was assessed in controls. SHEsis software was used for allele and haplotype frequency comparisons, and Haploview software for linkage disequilibrium (LD) analysis.

Datasets

  • MG Patient Cohort: 215 adult MG patients.
  • Healthy Control Cohort: 235 ethnically matched healthy individuals.

No new benchmarks were introduced; the study utilized existing populations for comparison.

Key Insights and Ideas

  • TNFAIP3 rs7749323 as a Risk Factor for LOMG: The most significant finding is the strong association between the A allele of the rs7749323 polymorphism in the TNFAIP3 gene and late-onset myasthenia gravis (LOMG) in the studied population. This suggests a specific genetic predisposition for this subtype of MG.
  • Specificity of the Association: The study highlights that this association appears to be specific to LOMG. No significant associations were found between the studied TNFAIP3 SNPs and other MG subgroups (e.g., thymoma-associated MG, early-onset MG, or AChR Ab-negative MG). This points towards a nuanced role of TNFAIP3 in MG pathogenesis, potentially influencing disease onset or progression in a subtype-specific manner.
  • Haplotype Analysis Reinforces Findings: The haplotype analysis, examining combinations of SNPs, further supported the association with LOMG, identifying a "GA" haplotype as a potential risk factor.
  • TNFAIP3's Role in Inflammation Regulation: The paper contextualizes these findings by referencing TNFAIP3's known function as a potent anti-inflammatory signaling molecule that modulates NF-κB and other inflammatory pathways. This biological role provides a plausible mechanism for how genetic variations in TNFAIP3 could influence autoimmune disease susceptibility.

Key Results

  • Allele Frequency: The rs7749323 A allele frequency was significantly higher in the LOMG group (7.4%) compared to age-matched healthy controls (2.4%). This translated to an odds ratio (OR) of 3.27 (95% CI: 1.01–10.6, P = .04).
  • Genotype Frequency: Carriers of the rs7749323 A allele (dominant model) were more frequent in the LOMG group (14.9%) than in age-matched healthy controls (4.8%), with an OR of 3.47 (95% CI: 1.04–11.6, P = .03).
  • Haplotype Association: The "GA" haplotype (formed by rs5029939 and rs7749323) was found to be a risk haplotype in the LOMG group (OR = 2.59, 95% CI: 1.02–4.61, P = .039).
  • No Association for rs5029939: The SNP rs5029939 did not show any significant association with MG susceptibility in any of the studied subgroups.

Limitations and Future Work

  • Limited Number of SNPs: The study focused on only two SNPs within the TNFAIP3 gene. The authors acknowledge that a broader investigation of other SNPs and genetic variations within the TNFAIP3 pathway is needed to fully elucidate its role in MG.
  • Underpowered Study: The authors suggest that the study might have been underpowered, potentially leading to false-negative results for other associations.
  • Sample Size and Cohort: While the sample size of 215 MG patients is reasonable, a larger cohort and more diverse populations would strengthen the findings and improve generalizability.
  • Future Directions: The authors propose conducting further studies with larger cohorts and a wider range of candidate SNPs to definitively establish the impact of TNFAIP3 gene variations on MG susceptibility. They also suggest that understanding these genetic mechanisms could inform future therapeutic strategies for MG, particularly for LOMG.

Summary updated

Abstract

In this study, we intended to genotype 2 single nucleotide polymorphisms (SNPs) of tumor necrosis factor α-induced protein 3 (TNFAIP3) genes and explore an association of TNFAIP3 genetic polymorphism with the patients of myasthenia gravis (MG) at clinical level. In brief, 215 of adult MG patients were divided into subgroups according to their clinical features, age of onset, thymic pathology, and autoantibodies. Two hundred thirty-five of healthy controls were also divided into subgroups with gender- and age-matched. The allele and genotype frequencies of subgrouped patients were found to be higher than those of healthy controls. The distribution of TNFAIP3 gene rs7749323*A allele of late onset MG (LOMG, with positive acetylcholine receptor antibody and without thymoma) subgrouped patients was also significantly higher than that of gender- and age-matched healthy controls (7.4% vs 2.4%, odds ratio [OR] = 3.27, 95% confidence interval [CI] 1.01–10.6, P = .04). Furthermore, analysis to the genotype frequencies indicates that the carriers of rs7749323*A allele of LOMG group became more frequent than that of age-matched healthy controls (14.9% vs 4.8%, OR = 3.47, 95% CI 1.04–11.6, dominant model: P = .03). It is interesting to notice that there is no significant association between the rs7749323 and susceptibility of other MG subgroups. Therefore, it is suggested that the SNPs in the 3′ flanking region (rs7749323) of TNFAIP3 gene and the genetic variations of TNFAIP3 gene may take an important role in the susceptibility of LOMG.
BibTeX
@inproceedings{yang2017tnfaip,
  author = {Hongwei Yang and Yanchen Xie and Yuan Zhao and Liang Sun and Xiaoquan Zhu and Shuhui Wang and Yongqiang Zhang and Ping Lei and Yunxiao Meng},
  title = {{TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis}},
  booktitle = {Medicine},
  year = {2017},
  doi = {10.1097/md.0000000000006798},
}
Figure